Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Peter Valent, Daniel J. Lenihan et al.|European Heart Journal|2021Cited by 589
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)Matthew M.Y. Lee, Naveed Sattar, J Petrie et al.|Circulation|2020Cited by 437
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trialPaul R. Kalra, Claes Christian Strom, John G.F. Cleland et al.|The Lancet|2022Cited by 367
Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection FractionChristopher Rush, Mark C. Petrie, Colin Berry et al.|JAMA Cardiology|2021Cited by 245
Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled TrialNovalia Sidik, Colin Berry, Bethany Stanley et al.|Circulation|2023Cited by 44